Kincell Bio, a cell therapy CDMO, has forged a new partnership to produce early-phase clinical material for an allogeneic cell therapy product. The deal extends Kincell Bio’s manufacturing capabilities following the acquisition of a GMP-ready facility in 2024.
The partnership reflects Kincell Bio’s expertise in allogeneic cell therapy production, a key focus for the company. Bruce Thompson, CEO of Kincell Bio, emphasized the company’s commitment to supporting customers’ clinical trials through critical CMC development and manufacturing expertise.
The collaboration underscores Kincell Bio’s unwavering dedication to innovation in cell therapy development and manufacturing. The company’s mission is to bring new cellular therapies to market and improve patient outcomes, as evidenced by its ongoing efforts to expand its partnership portfolio and enhance its manufacturing capabilities.
Kincell Bio’s manufacturing facilities in Research Triangle Park, NC, and Gainesville, FL, enable them to provide comprehensive services, including analytical development, process development, GMP manufacturing, testing, and release. The company’s expertise extends to immune cell therapies, such as autologous and allogeneic CAR-T, CAR-NK, and CAR-M programs, supporting innovative companies in the development of these transformative treatments.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
